Say Goodbye to Multiple Myeloma: Carvykti – The Revolutionary Cell Therapy that Prolongs Survival!
Description:
45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ — Johnson & Johnson (NYSE:JNJ) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd). With these data, CARVYKTI® is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as the second line. Findings were featured as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65). “The three-year follow-up data from the Phase 3 CARTITUDE-4 study show a statistically significant and clinically meaningful improvement in overall survival and quality-of-life measures with CARVYKTI versus standard therapies—meaningful results that have the potential to transform the multiple myeloma treatment landscape,” said Binod Dhakal, M.D.
How Will This Affect Me?
As an individual diagnosed with multiple myeloma, the introduction of CARVYKTI® offers hope for a longer and improved quality of life. With a 45 percent reduction in the risk of death and significant improvements in overall survival, this revolutionary cell therapy presents a promising alternative to standard treatments and has the potential to transform the treatment landscape for patients like you.
How Will This Affect the World?
The development of CARVYKTI® marks a significant advancement in the fight against multiple myeloma at a global level. By demonstrating superior results in prolonging survival and improving quality of life for patients, this innovative cell therapy has the potential to revolutionize the standard of care not only for lenalidomide-refractory multiple myeloma but also in the broader context of cancer treatment worldwide.
Conclusion:
With the groundbreaking results from the Phase 3 CARTITUDE-4 study showcasing the remarkable efficacy of CARVYKTI®, patients and healthcare professionals alike can look forward to a future where multiple myeloma is no longer as daunting a diagnosis. The significant reduction in the risk of death and the improvement in overall survival offered by this revolutionary cell therapy pave the way for a new era in the treatment of this challenging disease.
